Susan G. Komen’s 2022 Metastatic Breast Cancer (MBC) Impact Series will provide people living with metastatic breast cancer and their loved ones a safe, collaborative space to gather information related to MBC and discover practical resources to help make decisions for improved physical and emotional health.
Once you sign up for the 2022 MBC Impact Series, you will be automatically enrolled for all the sessions.
During each month’s event, you can participate in live sessions with leading experts, hear from individuals living with MBC and gather information from wellness experts.
You’ll also have the opportunity to ask our speakers questions, connect virtually with other attendees and interact with exhibitors.
Upcoming Events & Webinars
January 13, 8:30 a.m.-2:30 p.m. CST: (note CST time zone) MBC Impact Series presented by the Midwest Region. For information and to register, click here. Speakers include:Komen’s Chief Scientific Advisor Dr. George Sledge from Stanford University,
Komen Scholar Dr. Nikhil Wagle from the Dana-Farber Cancer Institute,
Recent Komen Scholar Dr. Danny Welch from the University of Kansas, and
Shirley Mertz, Founder and President, Metastatic Breast Cancer Network.
January 19, 12-12:30 p.m. CST: Register for our Facebook Live webinar with Dr. Daniel Stover about coupling liquid biopsies with diagnostic imaging and other new and exciting treatments in the MBC research pipeline.
January 22, 8:30 a.m.-1:00 p.m. CST: South Central MBC Virtual Conference. For more information and to register, click here.
Research, Treatment & Clinical Trials News
Since 1977, the San Antonio Breast Cancer Symposium (SABCS) has provided groundbreaking and practice-changing information on breast cancer research and treatment. This video from December features former Komen grantee Dr. Aditya Bardia and patient advocate Patty Spears discussing key discoveries, some with the potential to benefit those living with MBC, from December’s conference.
News for ER+/HER2- MBC: The first data from the EMERALD trial, presented by Dr. Aditya Bardia, demonstrated that elacestrant is the first oral selective estrogen receptor degrader (SERD) that has a progression free survival advantage over the standard of care endocrine therapy for people with ER+/HER2- MBC. The standard of care is a once monthly intramuscular injection (fulvestrant) or an aromatase inhibitor, whereas elacestrant is a once daily pill. There are some limitations but this is an important advancement in adding options to patients who do not tolerate fulvestrant well or have easy access to a monthly injection.
News for Triple Negative MBC: Final overall survival results from the KEYNOTE-355 trial that used pembrolizumab (also known as Keytruda) an immune checkpoint inhibitor (ICI), plus chemotherapy as a first line treatment for patients strongly positive for PD-L1 (described as a combined positive score CPS≥10) with metastatic triple-negative breast cancer showed a significant reduction in risk of death versus placebo combined with chemotherapy. A longer median overall survival and median progression-free survival were also observed in patients that had a CPS≥10 for PD-L1. This benefit was not seen in those patients that had a CPS>0 or CPS≥1. This study confirms pembrolizumab as a standard of care for mTNBC with strongly positive PD-L1.Wellness Resources
NEW! On the 3rd Wednesday of every month, we’ll be posting an MBC Wellness Wednesday video to our social media channels
(Facebook, Twitter and Instagram). These videos will feature short content from experts on a broad range of wellness topics for those living with MBC.
Information on Diet and Nutrition during treatment.
The Komen Breast Care Helpline is available Monday through Friday from 9:00 a.m. to 10:00 p.m. ET. at 1-877 GO KOMEN (1-877-465-6636) or email email@example.com for information, support and resource referrals. Se habla español.Sunshine, Faith and Family: Ashley’s Story
Ashley Fernandez was diagnosed with stage IV (metastatic) breast cancer when she was 31 years old. This is her story in her own words. Read more.